Surmounting Chemoresistance by Targeting the Y-Box Binding Protein-1

Anatomical Record

Volumn 295, Issue 2, 2012, Pages 215-222

  Inoue, Ikuyo ^a   Matsumoto, Ken ^b   Yu, Yingnan ^a   Bay, Boon Huat ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

Author keywords

Cancer therapy; Chemoresistance; Y box binding protein 1

Indexed keywords

ABC TRANSPORTER; CD44V ANTIGEN; CISPLATIN; CYCLINE; DOXORUBICIN; ENDONUCLEASE; FLUOROURACIL; LUNG RESISTANCE PROTEIN; MITOMYCIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN P73; VINCRISTINE; Y BOX BINDING PROTEIN 1;

CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CHEMOSENSITIVITY; DNA DAMAGE; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; TUMOR CELL;

DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; Y-BOX-BINDING PROTEIN 1;

EID: 84855760453     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.22401     Document Type: Review

References (87)

1. Ashizuka M, Fukuda T, Nakamura T, Shirasuna K, Iwai K, Izumi H, Kohno K, Kuwano M, Uchiumi T. 2002. Novel translational control through an iron-responsive element by interaction of multifunctional protein YB-1 and IRP2. Mol Cell Biol 22: 6375-6383.
2. Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K, Mapara MY, Winzer KJ, Dietel M, Dorken B, Royer HD. 1997. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 3: 447-450.
3. Basaki Y, Taguchi K, Izumi H, Murakami Y, Kubo T, Hosoi F, Watari K, Nakano K, Kawaguchi H, Ohno S, Kohno K, Ono M, Kuwano M. 2010. Y-box binding protein-1 (YB-1) promotes cell cycle progression through CDC6-dependent pathway in human cancer cells. Eur J Cancer 46: 954-965.
4. Bergmann S, Royer-Pokora B, Fietze E, Jürchott K, Hildebrandt B, Trost D, Leenders F, Claude JC, Theuring F, Bargou R, Dietel M, Royer HD. 2005. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res 65: 4078-4087.
5. Bourguignon LY, Peyrollier K, Xia W, Gilad E. 2008. Hyaluronan-CD44 interaction activates stem cell marker nanog, stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 283: 17635-17651.
6. Chattopadhyay R, Das S, Maiti AK, Boldogh I, Xie J, Hazra TK, Kohno K, Mitra S, Bhakat KK. 2008. Regulatory role of human AP-endonuclease (APE1/Ref-1) in YB-1-mediated activation of the multidrug resistance gene MDR1. Mol Cell Biol 28: 7066-7080.
7. Chernukhin IV, Shamsuddin S, Robinson AF, Carne AF, Paul A, El-Kady AI, Lobanenkov VV, Klenova EM. 2000. Physical and functional interaction between two pluripotent proteins, the Y-box DNA/RNA-binding factor, YB-1, and the multivalent zinc finger factor, CTCF. J Biol Chem 275: 29915-29921.
8. Chibi M, Meyer M, Skepu A, DJ GR, Moolman-Smook JC, Pugh DJ. 2008. RBBP6 interacts with multifunctional protein YB-1 through its RING finger domain, leading to ubiquitination and proteosomal degradation of YB-1. J Mol Biol 384: 908-916.
9. Cohen SB, Ma W, Valova VA, Algie M, Harfoot R, Woolley AG, Robinson PJ, Braithwaite AW. 2010. Genotoxic stress-induced nuclear localization of oncoprotein YB-1 in the absence of proteolytic processing. Oncogene 29: 403-410.
10. Didier DK, Schiffenbauer J, Woulfe SL, Zacheis M, Schwartz BD. 1988. Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box. Proc Natl Acad Sci USA 85: 7322-7326.
11. Duh JL, Zhu H, Shertzer HG, Nebert DW, Puga A. 1995. The Y-box motif mediates redox-dependent transcriptional activation in mouse cells. J Biol Chem 270: 30499-30507.
12. Evdokimova V, Ovchinnikov LP, Sorensen PH. 2006. Y-box binding protein 1: providing a new angle on translational regulation. Cell Cycle 5: 1143-1147.
13. Evdokimova V, Tognon C, Ng T, Sorensen PH. 2009a. Reduced proliferation and enhanced migration: two sides of the same coin? Molecular mechanisms of metastatic progression by YB-1. Cell Cycle 8: 2901-2906.
14. Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, Sorokin A, Ovchinnikov LP, Davicioni E, Triche TJ, Sorensen PH. 2009b. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 15: 402-415.
15. Faury D, Nantel A, Dunn SE, Guiot MC, Haque T, Hauser P, Garami M, Bognar L, Hanzely Z, Liberski PP, Lopez-Aguilar E, Valera ET, Tone LG, Carret AS, Del Maestro RF, Gleave M, Montes JL, Pietsch T, Albrecht S, Jabado N. 2007. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 25: 1196-1208.
16. Fillmore CM, Kuperwasser C. 2008. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10: R25.
17. Frank NY, Pendse SS, Lapchak PH, Margaryan A, Shlain D, Doeing C, Sayegh MH, Frank MH. 2003. Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J Biol Chem 278: 47156-47165.
18. Fujita T, Ito K, Izumi H, Kimura M, Sano M, Nakagomi H, Maeno K, Hama Y, Shingu K, Tsuchiya S, Kohno K, Fujimori M. 2005. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel. Clin Cancer Res 11: 8837-8844.
19. Gessner C, Woischwill C, Schumacher A, Liebers U, Kuhn H, Stiehl P, Jurchott K, Royer HD, Witt C, Wolff G. 2004. Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer. Eur Respir J 23: 14-19.
20. Gimenez-Bonafe P, Fedoruk MN, Whitmore TG, Akbari M, Ralph JL, Ettinger S, Gleave ME, Nelson CC. 2004. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate 59: 337-349.
21. Gluz O, Mengele K, Schmitt M, Kates R, Diallo-Danebrock R, Neff F, Royer HD, Eckstein N, Mohrmann S, Ting E, Kiechle M, Poremba C, Nitz U, Harbeck N. 2009. Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. J Clin Oncol 27: 6144-6151.
22. Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J, Liu A, Miu K, Watnick RS, Reinhardt F, McAllister SS, Jacks T, Weinberg RA. 2008. Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell 134: 62-73.
23. Guay D, Garand C, Reddy S, Schmutte C, Lebel M. 2008. The human endonuclease III enzyme is a relevant target to potentiate cisplatin cytotoxicity in Y-box-binding protein-1 overexpressing tumor cells. Cancer Sci 99: 762-769.
24. Hayakawa H, Uchiumi T, Fukuda T, Ashizuka M, Kohno K, Kuwano M, Sekiguchi M. 2002. Binding capacity of human YB-1 protein for RNA containing 8-oxoguanine. Biochemistry 41: 12739-12744.
25. Huang J, Tan PH, Li KB, Matsumoto K, Tsujimoto M, Bay BH. 2005. Y-box binding protein, YB-1, as a marker of tumor aggressiveness and response to adjuvant chemotherapy in breast cancer. Int J Oncol 26: 607-613.
26. Ise T, Nagatani G, Imamura T, Kato K, Takano H, Nomoto M, Izumi H, Ohmori H, Okamoto T, Ohga T, Uchiumi T, Kuwano M, Kohno K. 1999. Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. Cancer Res 59: 342-346.
27. Izumi H, Imamura T, Nagatani G, Ise T, Murakami T, Uramoto H, Torigoe T, Ishiguchi H, Yoshida Y, Nomoto M, Okamoto T, Uchiumi T, Kuwano M, Funa K, Kohno K. 2001. Y box-binding protein-1 binds preferentially to single-stranded nucleic acids and exhibits 3'-->5' exonuclease activity. Nucleic Acids Res 29: 1200-1207.
28. Janz M, Harbeck N, Dettmar P, Berger U, Schmidt A, Jurchott K, Schmitt M, Royer HD. 2002. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 97: 278-282.
29. Jurchott K, Bergmann S, Stein U, Walther W, Janz M, Manni I, Piaggio G, Fietze E, Dietel M, Royer HD. 2003. YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem 278: 27988-27996.
30. Jurchott K, Kuban RJ, Krech T, Bluthgen N, Stein U, Walther W, Friese C, Kielbasa SM, Ungethum U, Lund P, Knosel T, Kemmner W, Morkel M, Fritzmann J, Schlag PM, Birthmeier W, Krueger T, Sperling S, Sers C, Royer HD, Herzel H, Schafer R. 2010. Indentification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells. PLoS Genet 6: e1000231.
31. Kam NW, Liu Z, Dai H. 2005. Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. J Am Chem Soc 127: 12492-12493.
32. Kloks CP, Spronk CA, Lasonder E, Hoffmann A, Vuister GW, Grzesiek S, Hilbers CW. 2002. The solution structure and DNA-binding properties of the cold-shock domain of the human Y-box protein YB-1. J Mol Biol 316: 317-326.
33. Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. 2003. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays 25: 691-698.
34. Koike K, Uchiumi T, Ohga T, Toh S, Wada M, Kohno K, Kuwano M. 1997. Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett 417: 390-394.
35. Kuwano M, Uchiumi T, Hayakawa H, Ono M, Wada M, Izumi H, Kohno K. 2003. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Sci 94: 9-14.
36. Kuwano M, Oda Y, Izumi H, Yang SJ, Uchiumi T, Iwamoto Y, Toi M, Fujii T, Yamana H, Kinoshita H, Kamura T, Tsuneyoshi M, Yasumoto K, Kohno K. 2004. The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther 3: 1485-1492.
37. Lasham A, Lindridge E, Rudert F, Onrust R, Watson J. 2000. Regulation of the human fas promoter by YB-1, Puralpha and AP-1 transcription factors. Gene 252: 1-13.
38. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC. 2008. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100: 672-679.
39. Litman T, Druley TE, Stein WD, Bates SE. 2001. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58: 931-959.
40. Lorenz C, Hadwiger P, John M, Vornlocher HP, Unverzagt C. 2004. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett 14: 4975-4977.
41. Makino Y, Ohga T, Toh S, Koike K, Okumura K, Wada M, Kuwano M, Kohno K. 1996. Structural and functional analysis of the human Y-box binding protein (YB-1) gene promoter. Nucleic Acids Res 24: 1873-1878.
42. Mantwill K, Kohler-Vargas N, Bernshausen A, Bieler A, Lage H, Kaszubiak A, Surowiak P, Dravits T, Treiber U, Hartung R, Gansbacher B, Holm PS. 2006. Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents. Cancer Res 66: 7195-7202.
43. Matsumoto K, Wolffe AP. 1998. Gene regulation by Y-box proteins: coupling control of transcription and translation. Trends Cell Biol 8: 318-323.
44. Matsumoto K, Bay BH. 2005. Significance of the Y-box proteins in human cancers. J Mol Genet Med 1: 11-17.
45. Mertens PR, Harendza S, Pollock AS, Lovett DH. 1997. Glomerular mesangial cell-specific transactivation of matrix metalloproteinase 2 transcription is mediated by YB-1. J Biol Chem 272: 22905-22912.
46. Mertens PR, Steinmann K, Alfonso-Jaume MA, En-Nia A, Sun Y, Lovett DH. 2002. Combinatorial interactions of p53, activating protein-2, and YB-1 with a single enhancer element regulate gelatinase A expression in neoplastic cells. J Biol Chem 277: 24875-24882.
47. Mosby 2009. Mosby's medical dictionary. 8th ed. Maryland Heights, MO: Elsevier.
48. Mossink MH, van Zon A, Fränzel-Luiten E, Schoester M, Kickhoefer VA, Scheffer GL, Scheper RJ, Sonneveld P, Wiemer EA. 2002. Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics. Cancer Res 62: 7298-7304.
49. Mousseau M, Chauvin C, Nissou MF, Chaffanet M, Plantaz D, Pasquier B, Schaerer R, Benabid A. 1993. A study of the expression of four chemoresistance-related genes in human primary and metastatic brain tumours. Eur J Cancer 29A: 753-759.
50. Muñoz-Gámez JA, Quiles-Pérez R, Ruiz-Extremera A, Martín-Álvarez AB, Sanjuan-Nuñez L, Carazo A, León J, Oliver FJ, Salmerón J. 2011. Inhibition of poly (ADP-ribose) polymerase-1 enhances doxorubicin activity against liver cancer cells. Cancer Lett 301: 47-56.
51. Nekrasov MP, Ivshina MP, Chernov KG, Kovrigina EA, Evdokimova VM, Thomas AA, Hershey JW, Ovchinnikov LP. 2003. The mRNA-binding protein YB-1 (p50) prevents association of the eukaryotic initiation factor eIF4G with mRNA and inhibits protein synthesis at the initiation stage. J Biol Chem 278: 13936-13943.
52. Ohga T, Koike K, Ono M, Makino Y, Itagaki Y, Tanimoto M, Kuwano M, Kohno K. 1996. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 56: 4224-4228.
53. Ohga T, Uchiumi T, Makino Y, Koike K, Wada M, Kuwano M, Kohno K. 1998. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J Biol Chem 273: 5997-6000.
54. Okamoto T, Izumi H, Imamura T, Takano H, Ise T, Uchiumi T, Kuwano M, Kohno K. 2000. Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression. Oncogene 19: 6194-6202.
55. Rabik CA, Dolan ME. 2007. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23.
56. Sakura H, Maekawa T, Imamoto F, Yasuda K, Ishii S. 1988. Two human genes isolated by a novel method encode DNA-binding proteins containing a common region of homology. Gene 73: 499-507.
57. Sawaya BE, Khalili K, Amini S. 1998. Transcription of the human immunodeficiency virus type 1 (HIV1) promoter in central nervous system cells: effect of YB-1 on expression of the HIV-1 long terminal repeat. J Gen Virol 79: 239-246.
58. Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ. 1995. The drug resistance-related protein LRP is the human major vault protein. Nat Med 1: 578-582.
59. Schittek B, Psenner K, Sauer B, Meier F, Iftner T, Garbe C. 2007. The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int J Cancer 120: 2110-2118.
60. Shibahara K, Sugio K, Osaki T, Uchiumi T, Maehara Y, Kohno K, Yasumoto K, Sugimachi K, Kuwano M. 2001. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 7: 3151-3155.
61. Shibahara K, Uchiumi T, Fukuda T, Kura S, Tominaga Y, Maehara Y, Kohno K, Nakabeppu Y, Tsuzuki T, Kuwano M. 2004. Targeted disruption of one allele of the Y-box binding protein-1 (YB-1) gene in mouse embryonic stem cells and increased sensitivity to cisplatin and mitomycin C. Cancer Sci 95: 348-353.
62. Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, Kidani A, Yokomizo A, Naito S, Kohno K. 2008. Twist promotes tumor cell growth through YB-1 expression. Cancer Res 68: 98-105.
63. Shiota M, Izumi H, Tanimoto A, Takahashi M, Miyamoto N, Kashiwagi E, Kidani A, Hirano G, Masubuchi D, Fukunaka Y, Yasuniwa Y, Naito S, Nishizawa S, Sasaguri Y, Kohno K. 2009. Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth. Cancer Res 69: 3148-3156.
64. Shiota M, Yokomizo A, Tada Y, Uchiumi T, Inokuchi J, Tatsugami K, Kuroiwa K, Yamamoto K, Seki N, Naito S. 2010. P300/CBP-associated factor regulates Y-box binding protein-1 expression and promotes cancer cell growth, cancer invasion and drug resistance. Cancer Sci 101: 1797-1806.
65. Shnyreva M, Schullery DS, Suzuki H, Higaki Y, Bomsztyk K. 2000. Interaction of two multifunctional proteins. Heterogeneous nuclear ribonucleoprotein K and Y-box-binding protein. J Biol Chem 275: 15498-15503.
66. Sorokin AV, Selyutina AA, Skabkin MA, Guryanov SG, Nazimov IV, Richard C, Th'ng J, Yau J, Sorensen PH, Ovchinnikov LP, Evdokimova V. 2005. Proteasome-mediated cleavage of the Y-box-binding protein 1 is linked to DNA-damage stress response. EMBO J 24: 3602-3612.
67. Stein U, Jurchott K, Walther W, Bergmann S, Schlag PM, Royer HD. 2001. Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters. J Biol Chem 276: 28562-28569.
68. Stein U, Bergmann S, Scheffer GL, Scheper RJ, Royer HD, Schlag PM, Walther W. 2005. YB-1 facilitates basal and 5-fluorouracil-inducible expression of the human major vault protein (MVP) gene. Oncogene 24: 3606-3618.
69. Stratford AL, Habibi G, Astanehe A, Jiang H, Hu K, Park E, Shadeo A, Buys TP, Lam W, Pugh T, Marra M, Nielsen TO, Klinge U, Mertens PR, Aparicio S, Dunn SE. 2007. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Breast Cancer Res 9: R61.
70. Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, Yorida E, Turbin D, Dedhar S, Nelson C, Pollak M, Leighton Grimes H, Miller K, Badve S, Huntsman D, Blake-Gilks C, Chen M, Pallen CJ, Dunn SE. 2005. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 24: 4281-4292.
71. Swamynathan SK, Varma BR, Weber KT, Guntaka RV. 2002. Targeted disruption of one allele of the Y-box protein gene, Chk-YB-1b, in DT40 cells results in major defects in cell cycle. Biochem Biophys Res Commun 296: 451-457.
72. Takahashi M, Shimajiri S, Izumi H, Hirano G, Kashiwagi E, Yasuniwa Y, Wu Y, Han B, Akiyama M, Nishizawa S, Sasaguri Y, Kohno K. 2010. Y-box binding protein-1 is a novel molecular target for tumor vessels. Cancer Sci 101: 1367-1373.
73. Tay WL, Yip GW, Tan PH, Matsumoto K, Yeo R, Ng TP, Kumar SD, Tsujimoto M, Bay BH. 2009. Y-Box-binding protein-1 is a promising predictive marker of radioresistance and chemoradioresistance in nasopharyngeal cancer. Mod Pathol 22: 282-290.
74. To K, Fotovati A, Reipas KM, Law JH, Hu K, Wang J, Astanehe A, Davies AH, Lee L, Stratford AL, Raouf A, Johnson P, Berquin IM, Royer HD, Eaves CJ, Dunn SE. 2010. Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res 70: 2840-2851.
75. Toh S, Nakamura T, Ohga T, Koike K, Uchiumi T, Wada M, Kuwano M, Kohno K. 1998. Genomic organization of the human Y-box protein (YB-1) gene. Gene 206: 93-97.
76. Uchiumi T, Kohno K, Tanimura H, Matsuo K, Sato S, Uchida Y, Kuwano M. 1993. Enhanced expression of the human multidrug resistance 1 gene in response to UV light irradiation. Cell Growth Differ 4: 147-157.
77. Uramoto H, Izumi H, Ise T, Tada M, Uchiumi T, Kuwano M, Yasumoto K, Funa K, Kohno K. 2002. p73 Interacts with c-Myc to regulate Y-box-binding protein-1 expression. J Biol Chem 277: 31694-316702.
78. Wachowiak R, Thieltges S, Rawnaq T, Kaifi JT, Fiegel H, Metzger R, Quaas A, Mertens PR, Till H, Izbicki JR. 2010. Y-box-binding protein-1 is a potential novel tumour marker for neuroblastoma. Anticancer Res 30: 1239-1242.
79. Wahl GM, Carr AM. 2001. The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat Cell Biol 3: E277-E286.
80. Walton SP, Wu M, Gredell JA, Chan C. 2010, Designing highly active siRNAs for therapeutic applications. FEBS J 277: 4806- 4813.
81. Wolffe AP, Tafuri S, Ranjan M, Familari M. 1992. The Y-box factors: a family of nucleic acid binding proteins conserved from Escherichia coli to man. New Biol 4: 290-298.
82. Wolffe AP. 1994. Structural and functional properties of the evolutionarily ancient Y-box family of nucleic acid binding proteins. Bioessays 16: 245-251.
83. Yahata H, Kobayashi H, kamura T, Amada S, Hirakawa T, Kohno K, Kuwano M, Nakano H. 2002. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer. J Cancer Res Clin Oncol 128: 621-626.
84. Yang JY, Ha SA, Yang YS, Kim JW. 2010. p-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistance. BMC Cancer 10: 388.
85. Yu YN, Yip GW, Tan PH, Thike AA, Matsumoto K, Tsujimoto M, Bay BH. 2010. Y-box binding protein 1 is up-regulated in proliferative breast cancer and its inhibition deregulates the cell cycle. Int J Oncol 37: 483-492.
86. Zheng J, Jing W, Orentas RJ. 2009. Discovery of YB-1 as a new immunological target in neuroblastoma by vaccination in the context of regulatory T cell blockade. Acta Biochim Biophys Sin (Shanghai) 41: 980-990.
87. Zou Y, Chien KR. 1995. EFIA/YB-1 is a component of cardiac HF-1A binding activity and positively regulates transcription of the myosin light-chain 2v gene. Mol Cell Biol 15: 2972-2982.